Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Bullous pemphigoid: three atypical cases

Eleonora Ruocco, Anna Aurilia, Giovanni Simonetti

    Acta Dermato-Venereologica
    |October 2, 2002
    PubMed
    Summary

    No abstract available in PubMed .

    Related Experiment Videos

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Distinctive Reactivity to the C-terminal Epitope of BP180 Characterizes Immune Checkpoint Inhibitor-associated Bullous Pemphigoid, and an ELISA Based on the BP180 Ectodomain Enables Prompt Diagnosis in a Subset of Patients.

    Acta dermato-venereologica·2026
    Same author

    Web-based family-reported outcomes to assess family functioning in multiple sclerosis: an Italian multicenter digital survey.

    International journal of medical informatics·2026
    Same author

    Assessment on effectiveness and safety of plasma radiofrequency ablation in facial and eye rejuvenation: a preliminary retrospective study.

    Dermatology reports·2026
    Same author

    Human Papillomavirus in Bowen Disease: Site-Specific Prevalence, Genotype Distribution, and Clinical Implications Across Nail Apparatus, Cutaneous, and Anogenital Sites.

    International journal of molecular sciences·2026
    Same author

    Dupilumab for Prurigo Nodularis: Real-World Outcomes Up to 104 Weeks from the DUPItaPN Study.

    Clinical and experimental dermatology·2026
    Same author

    Does the response to bimekizumab vary according to previous therapy with methotrexate<i> versus </i>cyclosporine?

    Dermatology reports·2026